The recent FDA approval of the ACE Xtend Remote Control Unit will have a positive impact on patients and healthcare personnel as it helps in shortening the durations of interventional percutaneous procedures, says GlobalData, a leading data and analytics company.

The XACT ACE Robotic System is a device designed to increase the success of interventional percutaneous procedures by using image-guided planning, accurate robotic insertion, real-time monitoring and the S-Drive patented technology that allows continuous adaptation of the trajectory of the movement of the insertion tool to reach the determined target with more accuracy and precision.

Elia Garcia, Medical Analyst at GlobalData, comments: “Robotic surgery has developed rapidly during the last decade. New concepts have emerged from this technology, such as telesurgery or virtual training. The development of remote technology specifically in this area of ​​medicine is essential to reduce the time of radioactive exposure during procedures and ensure the safety of medical personnel.”

Interventional percutaneous procedures in combination with guided-navigation robotic systems tend to reduce complications for patients, thereby help in making recovery and hospital discharge usually faster. With its remote controlling capability, this technology will ensure the safety of health personnel in the long term, apart from addressing physician shortage.

Garcia adds: “Robotic surgery has shown to have numerous advantages that help improve surgical techniques. The approval of ACE Xtend Remote Control Unit will enable specialists to execute planning, monitoring and insertion and steering functions remotely, increasing the workflow efficiency of the procedure.”